Long-Term Follow-Up of Faricimab Intravitreal Injections in Naïve Neovascular Age-Related Macular Degeneration
Faricimab showed efficacy in the treatment of naïve nAMD patients with an improvement of many anatomical and functional parameters at 44 weeks, allowing the maintenance of a treatment regimen for most patients equal to or greater than 12 weeks.
Authors
- Raffaella Aloia
- Marta Di Nicola (ORCID: https://orcid.org/0000-0003-1748-1931)
- Federico Formenti (ORCID: https://orcid.org/0000-0003-4289-0761)
- Luca Belloni Baroni
- Marzia Passamonti
- Lisa Toto
- Rodolfo Mastropasqua
- Alberto Quarta
- Maria Ludovica Ruggeri
Institutions
- University of Chieti-Pescara (IT)
- Johns Hopkins Hospital (US)
Publication Details
- Journal
- Ophthalmic Research
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1159/000550307
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00